


**PRODUCT: LY2228820**

**ALTERNATE NAMES:** LY 2228820; LY-2228820; LY2228820 dimesylate; Ralimetini b dimesylate; 5-(2-(tert-butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethan esulfonate; 5-[2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)imidazo[4,5-b]pyridin-2-amine; methane sulfonic acid

**CATALOG#:** B1702-5, -25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>26</sub>H<sub>37</sub>FN<sub>6</sub>O<sub>6</sub>S<sub>2</sub>

**MOLECULAR WEIGHT:** 612.74

**CAS NUMBER:** 862507-23-1 (mesylate)

**APPEARANCE:** Solid powder

**SOLUBILITY:** DMSO

**PURITY:** >98%

**STORAGE:** Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

**DESCRIPTION:** LY2228820 is a novel and potent inhibitor of p38 MAPK with IC<sub>50</sub> of 7 nM in a cell-free assay, but does not alter p38 MAPK activation.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCES:**

1. Campbell RM1 et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74.
2. Ishitsuka K1 et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008 May;141(5):598-606.

**RELATED PRODUCTS:**

- Alsterpaullone (Cat. No. 1897-1, 5)
- AZD-6244 (Cat. No. 2234-5, 25)
- BIX01289 (Cat. No. 2670-1, 5)
- Butyrolactone I (Cat. No. 1690-200)
- Doramapimod (Cat. No. 1954-5, 25)
- Flavopiridol (Cat. No. 2090-1, 5)
- 10Z-Hymenialdisine (Cat. No. 2212-250, 1000)
- Kenpaullone (Cat. No. 1904-1)
- MEK-162 (Cat. No. 2254-5, 25)
- PD1834352 (CI-1040) (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- RO-3306 (Cat. No. 2039-1, 5)
- Roscovitine (Cat. No. 1950-1, 5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- SB202190 (Cat. No. 2493-5, 25)
- Sorafenib (Cat. No. 1594-25, 100)
- TAK733 (Cat. No. 2460-5, 25)
- TG003 (Cat. No. 1905-5, 25)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1, 5)
- VX-745 (Cat. No. 2812-5, 25)

**USAGE:** **FOR RESEARCH USE ONLY! Not to be used in humans**